Quest Diagnostics has introduced a new flow cytometry measurable residual disease (MRD) blood test for myeloma, a cancer arising from abnormal plasma cells.
The test aims to enhance ultra-sensitive detection of MRD through a non-invasive approach. It is designed to provide sensitivity comparable to next-generation sequencing methods, but at a significantly lower cost, supporting improved patient care.
The Quest test offers next-generation flow cytometry capabilities and uses only non-invasive blood samples. It does not require baseline aspirate samples as next-generation sequencing (NGS) does.
Download sample pages of selected reports
Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.
It also features five-day specimen stability, compared to three or fewer days with conventional flow cytometry, which could improve access when specimen transport times are longer. This feature aims to make the test feasible even when baseline samples are unavailable.
Quest expects the new blood test will also support response monitoring in clinical trials. The FDA issued draft guidance in January 2026 endorsing MRD as a primary endpoint in multiple myeloma drug trials for accelerated approval.
Quest senior vice-president and chief medical officer Yuri Fesko said: “Our flow cytometry MRD for myeloma test harnesses cutting-edge science and technology to deliver ultra-sensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system.
“This new test merges this elite performance with improved access, given Quest’s approximately 7,000 phlebotomy sites across the US, helping to illuminate a path to better health for more patients.”
Quest provides oncology testing services, including the Haystack MRD test for solid tumours. This offering extends the company’s portfolio of haematopathology and molecular oncology testing services.
In September 2025, Quest introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients’ genetic responses to specific medications.
Unlock up to 35% savings on GlobalData reports
Use the code at checkout in the report store
-
20% OFF
Buy 2 reports
Use code:
Bundle20
-
25% OFF
Buy 3 reports
Use code:
Bundle25
-
30% OFF
Buy 4 reports
Use code:
Bundle30
-
35% OFF
Buy 5+ reports
Use code:
Bundle35
Valid on all reports priced $995 and above. Cannot be combined with other offers.
Still deciding what will work best for your business?
Ask our experts for help.
Enquire before buying
